Menu Search
Equities

Vimian Group AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VIMGF:PKL

Vimian Group AB

Actions
  • Price (USD)2.77
  • Today's Change0.00 / 0.00%
  • Shares traded569.00
  • 1 Year change--
  • Beta1.1421
Data delayed at least 15 minutes, as of Dec 17 2025 20:58 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vimian Group AB is a Sweden-based veterinary company. The Company is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The Company invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.

  • Revenue in SEK (TTM)4.49bn
  • Net income in SEK329.66m
  • Incorporated2020
  • Employees1.20k
  • Location
    Vimian Group ABRiddargatan 19STOCKHOLM 114 57SwedenSWE
  • Phone+46 703358449
  • Websitehttps://vimian.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VIMIAN:STO since
announced		Transaction
value
I-Vet SrlAnnounced23 Dec 202523 Dec 2025Announced-9.28%--
AllAccem IncDeal completed13 Jun 202513 Jun 2025Deal completed-35.64%--
Data delayed at least 15 minutes, as of Feb 16 2026 10:56 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.